

<b>Reference:</b>	FOI.16501.25
<b>Subject:</b>	Biologic medications
<b>Date of Request:</b>	3 February 2025

**Requested:**

- How many patients were treated in January 2025 (or latest available month) by the Dermatology department with the following drugs:
  - Abrocitinib (Cibinqo)
  - Baricitinib (Olumiant)
  - Dupilumab (Dupixent)
  - Lebrikizumab (Ebglyss)
  - Omalizumab (Xolair)
  - Tralokinumab (Adtralza)
  - Upadacitinib (Rinvoq)
- How many patients were treated in January 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:
  - Benralizumab (Fasenra)
  - Dupilumab (Dupixent)
  - Mepolizumab (Nucala)
  - Omalizumab (Xolair)
  - Reslizumab (Cinqaero)
  - Tezepelumab (Tezspire)

**Response:**

- Hywel Dda University Health Board (UHB) provides within the table below, data held by its Pharmacy Department for the number of patients that were issued with the named biologic medications for secondary care only by the Dermatology Department, during January 2025.

Medication	Number
Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	0
Dupilumab (Dupixent)	50
Lebrikizumab (Ebglyss)	0
Omalizumab (Xolair)	7
Tralokinumab (Adtralza)	6
Upadacitinib (Rinvoq)	5

- The UHB provides within the table below, data held by its Pharmacy Department for the number of patients that were issued with the named biologic medications for secondary care only by the Respiratory Medicine Department, during January 2025.

Medication	Number
Benralizumab (Fasenra)	29
Dupilumab (Dupixent)	5
Mepolizumab (Nucala)	9
Omalizumab (Xolair)	0
Reslizumab (Cinqaero)	0
Tezepelumab (Tezspire)	21